Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Rhythm Pharmaceuticals Inc (NQ: RYTM ) 49.78 +0.21 (+0.42%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 638,194 Open 50.03 Bid (Size) 48.10 (1) Ask (Size) 52.38 (1) Prev. Close 49.57 Today's Range 48.48 - 51.14 52wk Range 17.06 - 53.92 Shares Outstanding 60,972,909 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Rhythm Pharmaceuticals Announces New Employment Inducement Grants July 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Appointment of Alastair Garfield, Ph.D., as Chief Scientific Officer July 08, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Performance YTD +10.30% +10.30% 1 Month +17.05% +17.05% 3 Month +27.61% +27.61% 6 Month +19.35% +19.35% 1 Year +184.46% +184.46% More News Read More Rhythm Pharmaceuticals Receives Positive CHMP Opinion for ▼IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients between 2 and 6 years old with Bardet Biedl Syndrome or POMC, PCSK1, or LEPR Deficiency June 28, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Analyst Expectations For Rhythm Pharmaceuticals's Future April 26, 2024 Via Benzinga 5 Analysts Assess Rhythm Pharmaceuticals: What You Need To Know April 10, 2024 Via Benzinga Analyst Expectations For Rhythm Pharmaceuticals's Future February 22, 2024 Via Benzinga Rhythm Pharmaceuticals Announces New Employment Inducement Grants June 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Presents Patient-reported Experiences with Hyperphagia in Hypothalamic Obesity at ENDO 2024 June 03, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conference June 03, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome May 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants May 09, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire The 3 Best Nasdaq Stocks to Buy in May 2024 May 07, 2024 Via InvestorPlace RYTM Stock Earnings: Rhythm Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 May 07, 2024 Via InvestorPlace Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update May 07, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Presents Data from Phase 3 Pediatrics Trial at Pediatric Endocrine Society Annual Meeting May 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Publication of Results from Phase 2 Study of Setmelanotide for the Treatment of Hypothalamic Obesity in The Lancet Diabetes & Endocrinology April 29, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 April 24, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Jim Cramer Is 'Willing To Let This Pharma Stock Catch Fire,' Advises Not To Sell McKesson April 19, 2024 Via Benzinga Rhythm Pharmaceuticals Announces New Employment Inducement Grants April 16, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Secures $150 Million in Convertible Preferred Stock Financing April 01, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire 7 Stocks That Will Drive the Weight Loss Drugs Market March 28, 2024 Via MarketBeat Rhythm Pharmaceuticals Announces First Patient Dosed in Phase 1 Trial Evaluating RM-718, a Weekly MC4R-specific Agonist March 25, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces New Employment Inducement Grants March 11, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Participation at Upcoming Investor Conferences March 06, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Rhythm Pharmaceuticals Announces Clinical Development Plan of Setmelanotide for Hypothalamic Obesity in Japan February 22, 2024 From Rhythm Pharmaceuticals, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.